# Miro Sciences Raises A$6M to Fast Track Commencement of Phase 2 Clinical Trial

***StemSmart™ treatments to commence for patients with Refractory Crohn's Disease in Australia and the United States***

**Highlights:**

- **Miro Sciences (ASX: MSX) has received firm commitments for an oversubscribed Placement to domestic and international, professional and sophisticated Investors.**
- **The Placement will raise A$6 million (before costs) at $0.040 per new share.**
- **Proceeds will allow the Company to fast-track commencement of its Phase 2 clinical trial of StemSmart™ in patients with Refractory Crohn's Disease, in Australia and the United States.**
- **Westar Capital Limited acted as sole Lead Manager to the Placement.**

**Miro Sciences (ASX: MSX) (formerly NeuroScientific Biopharmaceuticals (ASX: NSB)) ("Miro Sciences", "MSX" or the "Company")**, an innovative Australian biotechnology company developing novel technologies targeting immune-mediated inflammatory diseases with large treatment-resistant populations, is pleased to announce that it has received firm commitments for an oversubscribed placement (the "Placement") of ordinary shares ("New Shares") to domestic and international, professional and sophisticated investors.

The Placement will be conducted in two tranches and provide total funding of A$6 million (before costs). New Shares will be issued at A$0.040 per share.

**MSX Chief Executive Officer, Nathan Smith commented:**

> *"This funding allows MSX to fast-track commencement of its Phase 2 clinical trial in Refractory Crohn's Disease. The success of the Placement in a challenging market reflects the hard work of our team, our Board and our partners as we continue to methodically deliver critical operational, regulatory and clinical milestones. We are excited by the path ahead and extend our gratitude to our investors and Westar Capital for their support."*

## Use of Funds

Proceeds from the Placement will directly support commencement of the randomised, double-blinded, placebo-controlled Phase 2 clinical trial for treating patients with Refractory Crohn's Disease with Miro Sciences' StemSmart™ mesenchymal stem cell product in Australia and the United States. Activities being funded include:

- StemSmart™ product manufacturing
- Phase 2 clinical trial initiation and patient treatment
- Regulatory strategy, medical advisory and governance, quality assurance and accreditation
- Collaborations and ongoing development activities
- General working capital to support corporate objectives

## Details of the Placement

The issue of 97,429,500 New Shares will be completed utilising the Company's ASX Listing Rule 7.1 and 7.1A placement capacity ("Tranche 1"). The issue of the remaining 52,570,500 New Shares is subject to shareholder approval in accordance with the Listing Rules ("Tranche 2").

The Company anticipates holding a general meeting of shareholders to approve the issue of securities requiring shareholder approval in accordance with the timetable set out below. The Company will provide further details on the general meeting, as soon as practicable.

## Indicative Timetable

| Event | Date |
|---|---|
| Issue of Tranche 1 New Shares using ASX Listing Rule 7.1 and 7.1A | Friday 4 December 2026 |
| Dispatch of Notice of Meeting | December 2026 |
| General Meeting | On or around 15 February 2027 |
| Issue of Tranche 2 New Shares and broker options (subject to shareholder approval) | Mid-February 2027 |

*The above timetable is indicative only and remains subject to change at the Company's discretion, subject to compliance with the Corporations Act, the ASX Listing Rules and other applicable laws. The Company reserves the right to change the timetable, subject to regulatory requirements.*

Westar Capital Limited acted as sole lead manager to the Placement and will receive a $20k signing fee, 6% of the gross funds raised under the Placement, and subject to shareholder approval have the right to subscribe for 30 million unlisted options with an issue price of $0.0001, an exercise price of $0.08 each and a three-year expiry from the date of issue.

**This announcement is intended to lift the Company's Trading Halt, applied for and granted on Monday 23 November 2026.**

This announcement is authorised by the Board of **Miro Sciences Limited.**

For Further Information, please contact:

**Nathan Smith**
Chief Executive Officer
Miro Sciences Limited
ir@mirosciences.com

**Jane Morgan**
Investor and Media Relations
Jane Morgan Management
jm@janemorganmanagement.com.au

**About Miro Sciences Ltd**
Miro Sciences Limited (ASX: MSX), formerly NeuroScientific Biopharmaceuticals Limited (ASX: NSB), is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. MSX applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

**Targeting Crohn's Disease with StemSmart™ Technology**
MSX is prioritising the application of its proprietary StemSmart™ technology targeting refractory Crohn's - a severe and treatment-resistant form of the condition. NSB's StemSmart™ product is derived from adult human donor bone marrow-sourced MSCs that is produced using a patented manufacturing process developed at Royal Perth Hospital, Western Australia and designed to improve therapeutic activity and clinical response.

The Company is planning Phase 2 clinical trials to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn's disease, with the goal of making the treatment available to patients for whom current therapies remain inadequate.

**Forward Looking Statements**
This announcement may contain certain "forward-looking statements". Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

You are strongly cautioned not to place undue reliance on forward looking statements, including in respect of the financial or operating outlook for the Company. Except as required by law or any relevant listing rules of the ASX, the Company assumes no obligation to provide any additional or updated information or to update any forward-looking statements, whether as a result of new information, future events or results, or otherwise. Nothing in this announcement will, under any circumstances (including by reason of this announcement remaining available and not being superseded or replaced by any other presentation or publication with respect to the Company, or the subject matter of this announcement), create an implication that there has been no change in the affairs of the Company since the date of this announcement.